The importance of gut microbiota in health and disease is becoming increasingly evident, and there is a growing body of literature on the therapeutic potential of probiotics in GI disorders 2, 3 like irritable bowel syndrome (IBS) and many other conditions. The proposed mechanisms of action for the beneficial effects of probiotics include competitive exclusion of pathogenic microorganisms, inhibition of pathogen adhesion, production of anti-microbial substances and modulation of the immune system. [4] [5] [6] Studies in several animal models have indicated positive therapeutic results for probiotics in a range of conditions, such as asthma, 7 obesity, 8, 9 diabetes mellitus, 10 hypertension, 11, 12 and depression and anxiety; 13 however, definitive data from human studies are relatively sparse. There is some evidence for a beneficial effect of probiotics in humans in the prevention of hypertension 14 and improvement of the symptoms of schizophrenia, 15 depression 16 and Alzheimer's disease, 17 although further studies are needed to confirm these findings. Evaluation of the effect of probiotics in humans is complex due to differences in strains, patient populations and dosing. In addition, many clinical trials report conflicting findings, and results of meta-analyses have been published that compare non-identical probiotic strains, making the evidence difficult to interpret. A transparent and rigorous methodology is needed when evaluating the evidence because this topic remains complex.
Lower GI symptoms commonly require a visit to a physician, but the heterogeneity of symptoms presented and their underlying causes may limit the pharmacological treatment options offered because no single dominant drug therapy would be effective in all cases. Although new pharmacological treatments are emerging, challenges remain in terms of their ability to improve symptoms without incurring side effects. [18] [19] [20] [21] Current evidence suggests that probiotics in the diet may play a role in reducing uncomfortable lower GI symptoms in adults. Therefore, as before, the emphasis of the ESPCG updated evidence-based guidelines is on the potential role of probiotics in the management of lower GI symptoms in clinical practice.
2 | METHODS
| Design
The repeated consensus procedure was based on an updated systematic literature review and re-rating of statements by an expert panel.
| Systematic literature search
Placebo-controlled RCTs evaluating the effects of probiotics on lower GI symptoms were identified through a systematic literature review (based on Appraisal of Guidelines, Research and Evaluation
[AGREE] II criteria 22 ) capturing studies published since the original searches were conducted in January 2012. 1 The same search terms 
| Citation screening and full-text review
Identified publications were screened manually based on the title and abstract in accordance with 2009 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines 23 against predefined eligibility criteria (Table 1) . Full-text versions of all publications meeting the eligibility criteria at initial screening were reviewed to confirm eligibility.
| Data items collected and quality assessment
The same data items were collected and tabulated as in the original systematic review, including patient demographics, sample size, strain of probiotic, setting, primary and secondary endpoints, and results.
Of note, the term "probiotics" has been used throughout this publication to refer to products that contain probiotics, regardless of whether these are single or multiple strains. The additional step of a quality assessment was performed for each publication (in both the original and the updated review) using a modified version of the
Critical Appraisal Skills Programme (CASP) Checklist for Randomised
Controlled Trials, 24 as recommended by the National Institute for
Health and Care Excellence. 25 
| Delphi consensus
A modified Delphi process was used to review the original consensus statements in the light of the new evidence identified in the current updated systematic review. The Delphi process uses anonymous and iterative feedback and voting to achieve consensus among a panel of independent experts by means of stepwise The Consensus Group members reviewed both the original and new evidence on the use of probiotics in the management of lower GI symptoms. It was anticipated that 3 rounds of anonymous voting would be required to achieve consensus. Votes were cast using an online platform (Google Forms) and the results were analysed by the nonvoting Chair. For each statement, voters indicated their level of agreement on a scale from 1 to 6 (1 = strongly disagree; 2 = disagree with major reservation; 3 = disagree with minor reservation; 4 = agree with major reservation; 5 = agree with minor reservation; and 6 = strongly agree). Consensus was defined a priori as agreement by at least 67% of respondents. In some cases, the consensus statement is indication-specific; however, studies in other indications that provide relevant data are also described for completeness. In the following discussion, "significant" refers to a statistically significant result (P < 0.05).
After the updated consensus was completed, 3 consensus statements covering general considerations related to probiotic use in daily practice which referenced no specific studies individually (Statements 14, 15 and 16 in the original consensus) were moved to Section 4.
| RESULTS
The updated database searches identified 3176 articles (January 2012-July 2016) and 1090 articles (July 2016-June 2017; Figure 1 ).
After applying inclusion and exclusion criteria, 33 RCTs that reported on the effects of probiotics in the management of lower GI symptoms in clinical practice published since January 2012 were identified, and considered in conjunction with 37 RCTs included in the original systematic review. Of the 33, 6 publications were found in the June 2017 update. [27] [28] [29] [30] [31] [32] These could not be included in the consensus voting process; however, they were reviewed by the Steering Committee, which decided that the new evidence provided in these studies would not alter the results of the Delphi consensus and so could be included in our publication.
Collectively, the 70 studies investigated a total of 54 different probiotic products (containing 108 strains either alone or in combination) at doses ranging from 1 9 10 6 to 4.5 9 10 11 colony-forming units (CFU) per day, administered as 1, 2 or 3 doses. They predominantly contained bacteria (mostly lactobacilli and/or bifidobacteria); a few contained the yeast Saccharomyces. Of the 54 probiotic products, 28 were included in studies published since the original consensus, and the majority of these (22 of 28; 79%) were new probiotics that had not been evaluated in the original consensus.
T A B L E 1 Eligibility criteria for inclusion of publications examining probiotics in the management of lower GI symptoms Product adherence was addressed in 49 of the included studies.
In 42 studies, adherence to the intervention was assessed by counting empty containers or unused test substance returned at the end of the study and/or by participant self-reporting (in treatment diaries or during investigator visits). Three of these studies used faecal recovery of probiotic strains to measure adherence, and publications from 4 studies did not report the method of assessing adherence.
Where adherence data were reported (38 studies), the level of adherence was generally high. In the probiotic intervention groups, the proportion of participants who were adherent to treatment (taking >80% of doses) was >75%.
The majority of the 70 studies (Table S1) 27-96 focused on IBS (based on Rome I, II or III criteria or physician diagnosis; 34 studies),
antibiotic-associated diarrhoea (13 studies) or diarrhoea-associated
Helicobacter pylori eradication therapy (7 studies). Other conditions were investigated in 16 studies. Sixty-four studies provided evidence for the Delphi consensus (6 were identified after voting was completed). [27] [28] [29] [30] [31] [32] The evidence level was graded as "high" for 5 statements, "moderate" for 2, "low" for 4 and "very low" for 2. Table S2 summarises the studies and specific probiotics with evidence for (yogurt OR yoghurt OR probiotic* OR "lactic acid bacteria" OR "Streptococcus thermophilus" OR "S. thermophilus" OR "fermented milk" OR Bifidobacter* OR Lactobacill* OR Lactococc * OR "Saccharomyces " OR "Bacillus mesentericus" OR "B. mesentericus" OR " Enterococcus faecalis" OR "E. faecalis " OR "Enterococcus faecium" OR "E. faecium " OR "Bacillus clausii" OR "B. clausii " OR "Clostridium butyricum" OR "C. butyricum " OR "E. coli Nissle" OR "Escherichia coli Nissle" OR VSL#3) AND (IBS OR "irritable bowel syndrome" OR "abdominal distension" OR "gas evacuation" OR " visceral hypersensitivity " OR bloating OR flatulence OR flatus OR "abdominal pain" OR "digestive symptom" OR "stool consistency" OR "stool frequency" OR "stool quantity" OR "urgency" OR "faecal incontinence" OR "fecal incontinence" OR defecation OR "bowel movement" OR "bowel habit" OR transit OR constipation OR diarrhea OR diarrhoea) Figure 2 ). For each consensus statement, the result of the first (final) vote and the grade of supporting evidence are given, followed by a discussion of the evidence. Sometimes, a particular probiotic yielded conflicting results for a symptom/problem when it was investigated in different studies (see Table S2 ). Eight studies of 7 different probiotics evaluated overall IBS symptoms as a secondary endpoint only. Of these, 2 studies found a significant beneficial effect of 2 different probiotic treatments compared with placebo. 44, 55 One further dose-ranging study reported a beneficial effect of the specific probiotic treatment at the 1 9 10 8 CFU dose, but not at the lower and higher doses tested (1 9 10 6 and 1 9 10 10 CFU). 92 Four studies reported no significant differences between 4 different probiotic treatments and placebo 37, 66, 85, 94 and 1 study reported a negative effect of a probiotic treatment compared with placebo. 64 Of the 8 studies, 6 had been published since the original consensus. Four of the new studies (67%) reported no significant difference or a negative effect, compared with 1 of the 2 studies (50%) in the original consensus.
| IBS (global symptom assessment)
Statement 2: specific probiotics may help relieve overall symptom burden in some patients with IBS-C. Agreement: 100% (6, 12.5%; 5, 37.5%; 4, 50%; grade of evidence for effect: very low).
Supportive evidence: Five studies of 4 different probiotics evaluated overall IBS symptoms as a secondary endpoint in 577 patients with constipation-predominant IBS (IBS-C). Of these, 1 study reported a beneficial effect of the specific probiotic treatment (dosed at 2.5 9 10 10 at CFU per day) vs placebo. 33 Another study of the same probiotic found a significant improvement from baseline in the probiotic group but not in the placebo group in a subanalysis of patients with fewer than 3 bowel movements per week. 50 In a third study with a different probiotic treatment, an improvement was observed in the composite score of IBS symptoms in the probiotic group vs the placebo group, but this just failed to reach statistical significance. However, the total area under the curve of the composite score of IBS symptoms over 12 weeks was significantly lower in the probiotic group than in the placebo group (P = 0.03). 85 Two studies examining 2 different probiotics reported no significant improvement in symptoms vs placebo. 86, 92 Of the 5 studies, 2 had been published since the original consensus. Of the 2 new studies, 1 reported no significant improvement, compared with 1 of the 3 studies in the original consensus. | 1059 difference in the composite IBS symptom score between the probiotic group and the placebo group. showed a significant beneficial effect of specific probiotic treatments compared with placebo. 44, 46, 54, 74, 81, 85, 92 One of these found no statistically significant difference in abdominal pain/discomfort between probiotic and placebo in the overall population but a significantly greater improvement in the subgroup of patients with IBS-C. 85 Two studies (both included in the original consensus) had mixed results: 1
showed a trend towards a beneficial effect in the weekly symptom score for abdominal pain (and, in a secondary analysis, abdominal pain was reduced in a significantly greater proportion of the probiotic group than of the placebo group) 56 and the other showed no significant increase in the proportion of patients reporting symptom relief, but a significantly greater decrease in the abdominal pain score in the probiotic group than in the placebo group. 43 Abdominal pain was evaluated as a secondary endpoint only in 21 studies. Of these, 5 reported a significant beneficial effect of 5 different probiotics 33, 49, 55, 82, 96 (1 of which 33 also showed no significant effect in another study 50 ), 15 (examining 11 different probiotics) reported no significant effect 30, 36, 37, 50, 57, [59] [60] [61] 66, 80, 83, 88, [93] [94] [95] (of which 1 reported a nonsignificant trend in favour of probiotics vs placebo), 95 and another reported a negative effect of the specific probiotic treatment. 64 Of the 21 studies, 9 had been published since the original consensus. Seven of the new studies (78%) reported no significant difference or a negative effect, compared with 9 of the 12 studies (75%) in the original consensus.
Abdominal pain was examined in indications other than IBS in 8 studies, each investigating a different probiotic. Of these, 1 study (included in the original consensus) investigated abdominal pain as a primary endpoint in individuals with symptoms related to postprandial intestinal gas, and found a significant improvement in the probiotic group compared with the placebo group. 58 Seven studies examined abdominal pain as a secondary endpoint only, with 4 of these reporting no significant difference among 4 different probiotic treatments and placebo. 47 50 also showed a beneficial effect as a primary endpoint in another study 33 ). Of these studies, some found a significant effect only at one time point, 50 after a single dose 92 or only in patients with IBS-C. 85, 92 Fifteen studies reported no significant difference between 12 different probiotic treatments and placebo 30, 36, 37, 59, 60, 64, 66, 74, 80, 82, 83, 88, [94] [95] [96] (1 of these probiotics 60 also showed no significant effect on the primary endpoint). 61 Of the 23 studies, 11 had been published since the original consensus. Of the 11 new studies, 9 (82%) reported no significant difference, compared with 6 of the 12 studies (50%) in the original consensus.
Six studies investigated the effect of 6 different probiotics on distension/bloating in indications other than IBS. One of these studies (included in the original consensus) evaluated symptoms related to post-prandial intestinal gas as a primary endpoint in healthy individuals and reported no significant differences between the probiotic and placebo groups. 58 The remaining 5 studies (examining 5 different probiotics) evaluated distension/bloating as a secondary endpoint. Single studies reported no significant differences between the probiotic and control groups in women with mild digestive symptoms, 51 patients with functional GI disorders (FGID), 62 healthy individuals with low defecation frequency and abdominal discomfort, 47 and healthy patients with hard or lumpy stools in the past 2 years. 69 The fifth study, in individuals with lactose intolerance undergoing a hydrogen breath test, reported significantly reduced bloating in the group receiving the specific probiotic treatment but no significant improvement in the placebo group. 71 Of the 5 studies, 2 had been published since the original consensus; both of the new studies reported no significant difference between probiotic and control groups. showed no significant effect in another study 60 ); the significant effect was seen at 1 dose only in 1 of these studies, 92 and at week 16 (after follow-up) but not week 8 (end of treatment) in another study. 88 Of the 12 studies, 5 had been published since the original consensus. Of the 5 new studies, 4 (80%) reported no significant difference, compared with 4 of the 7 studies (57%) in the original consensus.
| Flatus
Seven studies examined the effect of 7 different probiotics on flatus in indications other than IBS. Four of these studies reported no significant effects on flatus (primary endpoint for 1 probiotic 58 and secondary endpoint for 3 other probiotics 62, 69, 73 ). Three studies reported a significant benefit of 3 different probiotic treatments on flatus (secondary endpoint) in women with mild digestive symptoms, 51 patients with functional GI symptoms 90 and individuals with lactose intolerance undergoing a lactose breath test. 71 Of the 7 studies, 2 had been published since the original consensus; both of the new studies reported no significant effect on flatus as a secondary endpoint. but not others (stool frequency and consistency, straining during evacuation and feelings of incomplete evacuation). 33 The 3 remaining studies did not detect any statistically significant effects of 3 different probiotic treatments on the relief of constipation. 36, 49, 74 Of the 4 studies, 2 had been published since the original consensus; both of the new studies reported no significant effect on constipation.
| Constipation
Seven studies of 7 different probiotics examined constipation in patients with broader FGID. Of these, 3 studies reported significant improvements in the relief of constipation, with 1 reporting an increase in defecation frequency 47 and another reporting a significant effect of the probiotic on stool consistency vs placebo (although this study did not show a significant effect of the probiotic on stool frequency vs placebo). 89 The third study did not provide a between-group statistical analysis; however, the decrease in constipation frequency score was approximately twofold greater in the probiotic groups than in the placebo group. 90 Four studies reported no significant effect of 4 different probiotic treatments; 31, 62, 68, 69 however, 1 of these studies showed a nonsignificant trend in favour of probiotics. 68 Of the 7 studies, 5 had been published since the original consensus. Of the 5 new studies, 3 (60%) reported no significant effect, compared with 1 of the 2 studies (50%) in the original consensus.
3.6 | Bowel habit 61 showed no significant benefit on the primary endpoint in another study 60 ). One found a trend to normalisation of stool consistency (P = 0.058); however, no significant effects on straining and feelings of incomplete evacuation were observed. 33 Another study reported a significant negative effect of the specific probiotic treatment. 64 Of the 22 studies, 7 had been published since the original consensus. Of the 7 new studies, 4 (57%) reported no significant effect or a negative effect, compared with 6 of the 15 studies (40%) in the original consensus.
Two studies (both included in the original consensus) examined the effects of probiotics on GI transit times. This was assessed as a primary endpoint in 1 study that reported no difference in GI transit times between the probiotic and placebo groups. 60 A second study showed significant improvements in the secondary endpoints of colonic and small bowel transit times in the probiotics vs placebo groups. 69 Two studies (including 1 published since the previous consensus) showed a beneficial effect of 2 different probiotics vs placebo on symptoms of diarrhoea, both of which were in patients with lactose intolerance.
71,73
Statement 10: in patients receiving antibiotic therapy, specific probiotics are helpful as adjuvant therapy to prevent or reduce the duration of associated diarrhoea. Agreement: 100% (6, 50%; 5, 50%;
grade of evidence for effect: high).
Supportive evidence: Thirteen studies of 10 different probiotics examined the prevention of antibiotic-associated diarrhoea and/or reduction in antibiotic-associated diarrhoea in 6091 patients who received antibiotics (although they were initiated in a hospital setting, these studies were included because of the relevance of antibiotic-associated diarrhoea to primary care). Of these, 11 studies examined antibiotic-associated diarrhoea as a primary endpoint. Six studies of 4 different probiotics administered at doses of 2 9 10 9 to 5 9 10 10 CFU per day 35, 38, 48, 53, 72, 78 (3 of which tested the same probiotic treatment) 35, 48, 78 showed a significant reduction in antibiotic-associated diarrhoea compared with placebo. One study reported a significant benefit of the probiotic vs placebo on the duration of antibiotic-associated diarrhoea only. 28 In contrast, 4 studies of 4 other probiotics reported no evidence that probiotics were effective in the prevention of antibiotic-associated diarrhoea vs placebo, 34 ,45,77,84 although 1 of these (an underpowered study) showed a nonsignificant reduction in antibiotic-associated diarrhoea. 84 Of the 11 studies, 6 had been published since the original consensus.
Of the 6 new studies, 3 (43%) reported no significant effect compared with 1 of the 5 studies (20%) in the original consensus. The 2 studies that assessed antibiotic-associated diarrhoea as only a secondary endpoint (1 study from the original consensus and 1 new study) found no difference between the probiotic and placebo groups.
29,76
Statement 11: in patients receiving H. pylori eradication therapy, specific probiotics are helpful as adjuvant therapy to prevent or reduce the duration/intensity of associated diarrhoea. Agreement: 100% (6, 87.5%; 5, 12.5%; grade of evidence for effect: high).
Supportive evidence: Seven studies evaluated the effect of 9 different probiotics (at doses of between 2 9 10 6 and 2 9 10 10 CFU per day) on diarrhoea as a side effect of H. pylori eradication therapy in 1480 patients. All the 5 studies examining H. pylori eradication therapy-associated diarrhoea as a primary endpoint (including 1 study published since the original consensus) reported a significant benefit of specific probiotic treatments compared with placebo. [39] [40] [41] [42] 70 However, the results for 2 of the studies were mixed, with a significant benefit of the specific probiotic treatment seen after 1 week, but not 2 weeks, in 1 study, 70 and significantly fewer days with diarrhoea and a shorter mean duration of diarrhoea episodes, but no significant difference in the frequency of diarrhoea episodes, in the probiotic group compared with the placebo group in another study. 42 Two studies (both published since the original consensus) were identified that assessed the occurrence of diarrhoea as a secondary endpoint, and both reported that the addition of probiotics to H. pylori eradication therapy significantly decreased diarrhoea as a side effect of treatment. questionnaire after 3 and 6 weeks of treatment; however, the probiotic group had a significantly greater proportion of responders for the discomfort dimension score than the placebo group at week 3.
50
Another study assessed 2 different probiotics in patients with FGID and found no significant differences between the probiotic and control groups for the Gastrointestinal Quality of Life Index (GIQLI) total score and well-being subscales (physical, social and mental; primary endpoint); however, use of the 36-item Short-Form Health Survey (SF-36; secondary endpoint) revealed significant improvements in physical functioning and/or "role-physical" domains with probiotics, but no significant changes in the control groups. 62 In 1 study, a significant reduction in "health-related worry" was observed in patients with IBS receiving the probiotic treatment vs placebo, but not in other domains of the IBS-QOL. 32 The remaining study in women with minor GI symptoms found no significant difference in the percentage of women reporting an improvement in GI well-being with probiotics vs placebo. 67 Nineteen studies assessed aspects of In 1 study of patients with IBS, 2 patients in the probiotic group discontinued involvement because of adverse events (moderate nausea and severe exanthema). However, the most frequent adverse events (fatigue, pruritus and diarrhoea) occurred equally often in the probiotic and placebo groups. 46 In another study of patients with IBS, 1 participant had a short stay in hospital for cervicobrachialgia 2 weeks after the end of the specific probiotic treatment; however, there was no organic explanation for this, and the patient continued in the trial. 64 Two patients with IBS treated with probiotics in a third study reported an itching rash, causing one patient to drop out. 36 A study of patients with IBS-C reported 16 adverse events, which were judged to be possibly linked to the research or to the study product by the investigators (10 events were reported in the active comparator group and 4 in the placebo group). 85 The dropout rate was significantly higher in the probiotic group than in the placebo group in the final study in patients with IBS (P = 0.048); however, most of the dropouts were due to noncompliance (n = 5), the requirement for an antibiotic (n = 5) or worsening of IBS symptoms (n = 2). 86 In a study of healthy athletes, there was a twofold increase in the number and duration of mild GI symptoms in the probiotic group compared with the placebo group, although the severity of these symptoms tended to be lower in the probiotic group than in the placebo group. 91 In a study examining the effects of probiotics on antibiotic-associated diarrhoea, the incidence of nonserious adverse events in the probiotic group was 2.0% compared with 0% in the placebo group. A causality assessment was carried out for all adverse events, and all were found to be of either probable or possible association. The reduced strength of evidence for the beneficial effect of probiotics was reflected in the levels of agreement reached for several statements during the wider Delphi voting process. For example, although consensus was achieved for Statement 1 ("Specific probiotics help to relieve overall symptom burden in some patients with IBS"), the individual levels of agreement were lower in the updated consensus ("strongly agree", 12.5%; "agree with minor reservation", 87.5%) than in the original consensus ("strongly agree", 40%; "agree with minor reservation", 50%; "agree with major reservation", 10%).
There was a reduction in the number of voters choosing to "strongly GI discomfort in the general adult population. 103 The systematic review identified 3 RCTs (2 of which were eligible for inclusion in our review). 51, 67 Individual data from 598 participants were evaluated in meta-analyses using random-effects models. Results from the analyses showed that consumption of the specific probiotic was associated with a significant improvement in overall GI discomfort reported that patients consuming the probiotic had a significantly higher chance of reduction in abdominal pain/discomfort (P = 0.0134) and improvement in stool consistency (P = 0.0003) than those consuming placebo. 104 Another recent meta-analysis examined the effects of the probiotic Bifidobacterium longum subsp. infantis 35624 in patients with IBS. 105 Analysis of data from the 5 studies that met the inclusion criteria (3 of which are included in our review) 37, 61, 92 showed that consumption of single probiotic B. for Statements 14 and 16) and the proportion of respondents voting to "strongly agree" with the statements (Figure 2 and Table S2 ).
To enable the current publication to be as up to date as possible and to avoid a time lag, 6 publications identified in the updated June 2017 database search did not undergo the Delphi consensus process. This could have had an impact on the levels of agreement of the voting panel. However, these publications were reviewed by the Steering Committee, members of which judged that the new evidence was in line with that previously reported and concluded that exclusion of the more recent publications would make little or no difference to the levels of agreement within the Delphi consensus.
As in the original systematic review, only studies that were randomised, placebo-controlled clinical trials of probiotics with suitable follow-up periods were included in the analysis in an attempt to obtain the highest quality data. Publications included in both the original and updated systematic reviews were subjected to quality assessment using the CASP checklist for RCTs. 24 This was carried out at the suggestion of the Steering Committee to allow the wider Delphi voting panel to judge the quality of the presented evidence and to use this to aid their decision-making. The majority of the publications (67%) were classified as being of "high quality" or above.
Despite the inclusion of adequately powered, high-quality studies, the results remain diverse. Variations in probiotic strain(s), doses and modes of administration, the health status of patients, and diet and concomitant medications (eg antibiotics and antacids) make comparisons between probiotics difficult.
Studies that did not strictly fit into the statement categories were excluded from those statements. For example, 1 study reported that B. lactis CNCM I-2494 (DN-173 010) produced a significant reduction in the "composite score of digestive symptoms"
when it was administered to healthy women reporting minor digestive symptoms compared with those receiving a control dairy product (P < 0.05; secondary endpoint). 67 However, this study was not included in the evidence base for Statement 1 because the statement focused on patients with IBS only. Only a small subset of the studies identified in the systematic review examined probiotics in healthy individuals, or patients with lactose malabsorption, other functional GI problems or mild lower GI symptoms; hence, specific statements were not prepared for these groups.
Other limitations of the current update that also applied to the original consensus 1 are as follows: the potential for publication bias; the potential for chance findings in secondary endpoints; the focus on adults (statements cannot be extended to children); and the presentation of physicians' rather than patients' perspectives. Overall, the studies identified in this systematic review, which were powered for specific primary endpoints, reported evidence supporting the effectiveness of probiotics for the relief of lower GI symptoms (especially overall GI symptom score, abdominal pain and bowel habit), improvement of HRQoL, and prevention of both antibioticassociated diarrhoea and diarrhoea associated with H. pylori eradication therapy. For safety outcomes, probiotics were comparable to placebo. When this evidence was presented to clinical experts, the panel reached consensus.
In the past 5 years, since the original review, the evidence for the effects of probiotics on lower GI symptoms has doubled. After evaluation of this evidence using the same rigorous methodology as before, the statements remain the same, and consensus was reached. This demonstrates that clinicians can remain confident that specific probiotics have a role in the management of lower GI symptoms. 
